Deals
Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch
- BioAge, Bicara look to buck the trend of recent IPO struggles
- Binary nature of drug development has kept generalists away
This article is for subscribers only.
After a string of lackluster deals, the biotech industry is looking to four debutants expected to price first-time share sales in the coming weeks to see if they can reignite the sector.
Drug developers that have raised more than $10 million in US initial public offerings this year have largely faltered with six of the 11 firms diving below their debut prices and the median decliner trading 45% below the offer price, data compiled by Bloomberg show.